Published in Blood Weekly, January 4th, 2007
This is the second clinical trial grant awarded to Semafore. The company recently announced receipt of a grant from Cancer Treatment Research Foundation (CTRF) to help fund a phase l trial of SF1126 in solid cancers. Both phase l trials are expected to commence in 2007.
The MMRF has awarded Semafore a $996,380 grant to help fund both the drug manufacturing and the patient costs of a phase l trial in relapsed and refractory multiple myeloma patients. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.